Biotech officials take closer look at Medicare bills.(Brief Article)

Officials at the Biotechnology Industry Organization sat down with member companies to examine Senate and House Medicare reform bills to make sure their interests are protected before a combined piece of legislation visits the president's desk. For the industry, one of the key issues in the bills deals with hospital outpatient prospective payment systems. Administered by the CMS, it determines at …